NCT02081924 Reproductive Hormones During Sustained Administration of Kisspeptin
| NCT ID | NCT02081924 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imperial College London |
| Condition | Fertility Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2014-04-02 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 76 participants in total. It began in 2014-04-02 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We want to find out what happens to reproductive hormone levels; Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH), testosterone and oestradiol when kisspeptin is administered to people for a period of 8 days each month, using either placebo (saline) or kisspeptin in doses of 0.1, 0.3 or 1.0 nmol/kg/hour.
Eligibility Criteria
Inclusion criteria: * Aged 18-60 years old * Ability to give informed consent * Secondary hypogonadism (or healthy participant) Exclusion criteria: * anaemia * medical problems such as severe heart, kidney or liver disease * blood donation in the last three months or intention to donate blood within 3 months of the end of the study * needle phobia * Poor venous access * Active psychiatric illness * Severe allergies * Impaired ability to provide full consent to take part in the study * Current alcohol or illicit drug dependence * Current pregnancy or breast feeding * Plans to conceive within 3 months of starting the study (barrier contraception must be used during and for 3 months after the end of the study) * Arthritis or any impairment of hand coordination which would preclude using a hormone pump
Contact & Investigator
Waljit Dhillo, PhD, FRCP
PRINCIPAL INVESTIGATOR
Imperial College London
Frequently Asked Questions
Who can join the NCT02081924 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Fertility Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02081924 currently recruiting?
Yes, NCT02081924 is actively recruiting participants. Contact the research team at ali.abbara@imperial.ac.uk for enrollment information.
Where is the NCT02081924 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT02081924 clinical trial?
NCT02081924 is sponsored by Imperial College London. The principal investigator is Waljit Dhillo, PhD, FRCP at Imperial College London. The trial plans to enroll 76 participants.